Skip to main content
TipRanks
Go Ultimate75% OFF

McKesson (MCK) AI Stock Analysis

2,338 Followers
MCK

McKesson

(NYSE:MCK)

Select Model
Rating:68Neutral
Price Target:$1,166.00â–²(5.52% Upside)
Action:reiterated
Date:11/05/26

The score is primarily supported by strong cash-flow generation and a very positive, guidance-raising earnings outlook. Offsetting factors are elevated balance-sheet risk (negative equity and rising debt) and a less attractive valuation (higher P/E with a low dividend yield), while technicals remain strong but somewhat overextended (high RSI).

Positive Factors
Cash generationStrong cash conversion gives McKesson internal funding for technology, operations, acquisitions, debt service, and shareholder returns. Free cash flow near net income also supports earnings quality, making the business more resilient despite its low-margin distribution model.
Negative Factors
Leverage and negative equityNegative equity and rising debt leave McKesson with a limited equity cushion and less financial flexibility if profitability weakens. Leverage also increases sensitivity to interest costs and operating setbacks, potentially constraining future investment and capital allocation.

McKesson Key Performance Indicators (KPIs)

Revenue by SegmentShows how revenue is distributed across various business segments, indicating which areas are growing or declining and where the company is focusing its efforts.

$0.00$25.00B$50.00B$75.00B$100.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

McKesson’s revenue mix is shifting: U.S. Pharmaceuticals remain the revenue backbone, but Oncology & Multispecialty has quickly become a material, higher‑margin growth engine via acquisitions, driving outsized operating‑profit gains and the upbeat oncology guidance. The sharp drop in International reflects the Norway divestiture and reclassification. Prescription Technology Solutions is steady; Medical‑Surgical is stable but earmarked for separation, which will free capital while adding near‑term financing and expense noise. Expect GLP‑1 and branded‑pricing volatility to create quarter‑to‑quarter forecast swings despite improving underlying margins.

Data provided by:The Fly

McKesson (MCK) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%MCK+30.60%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$127.58B
Dividend Yield
0.31%
Average Volume (3M)
800.59K
Price to Earnings (P/E)
28.4
Beta (1Y)
-0.10
Revenue Growth
8.19%
EPS Growth
21.01%
Country
US
Employees
42,300
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

McKesson Business Overview & Revenue Model

Company Description

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharma...

How the Company Makes Money

McKesson makes money primarily by distributing pharmaceuticals and healthcare products and charging customers for the value it provides in procurement, inventory management, logistics, and related services. 1) Pharmaceutical distribution (core revenu...

McKesson Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q2-2027)|% Change Since:3.33%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was strongly positive. McKesson reported broad-based revenue, operating profit, and adjusted EPS growth; raised fiscal 2027 guidance; highlighted strong cash generation, liquidity, shareholder returns, and strategic expansion in oncology, biopharma services, specialty care, and home-based infusion. The principal challenges were the medical-surgical operating profit decline and muted outlook, branded pharmaceutical pricing and generic conversions, higher interest expense, normalized prior authorization volumes, and uncertainty around 340B policy. These lowlights were outweighed by the company's reported performance, raised outlook, and strategic momentum.

Positive Updates

Strong Second-Quarter Revenue and EPS Growth
Second-quarter revenue increased 8% year over year to $111 billion, with growth across all four operating segments. Adjusted earnings per diluted share increased 18% to $11.68, or 24% excluding the prior-year Norway divestiture contribution and net gains from the sale of an equity investment and market positions within The U.S. Oncology Network.

Negative Updates

Medical-Surgical Solutions Operating Profit Decline
Medical-surgical solutions revenue increased 5% to $3.1 billion, but operating profit decreased 10% to $225 million. The decline was driven by lower contributions from the ambulatory care channel due to product mix, partially offset by growth in the extended care channel.

Company Guidance

For fiscal 27, McKesson raised adjusted earnings per diluted share guidance to $45.60 to $46.40, implying adjusted EPS growth of 17% to 19%, or 19% to 21% excluding the impact of the Norway divestiture and the net gains within the U.S. Oncology Network in fiscal 2026, versus a long term growth target of 13% to 16%; revenue growth is anticipated at 6% to 10% and operating profit growth at 12% to 16%. North American pharmaceutical revenue growth is anticipated at 5% to 9% and operating profit growth at 14% to 18%; oncology and multispecialty revenue growth at 20% to 24% and operating profit growth at 18% to 22%, or 22% to 26% excluding the net gains of $51 million in fiscal 2026; prescription technology solutions revenue growth at 2.5% to 6.5% and operating profit growth at 11% to 15%; and MedSurg revenue growth at 1% to 6% with operating profit to range from a 4% decline to flat. Corporate expenses are anticipated at the high end of the $580 million to $640 million range, interest expense at the high end of $380 million to $420 million, income attributable to noncontrolling interest at $290 million to $320 million, and the full year effective tax rate at 18% to 19%; free cash flow is anticipated at approximately $4.5 billion to $4.9 billion, approximately $5 billion of shares are expected to be repurchased during fiscal 27, and diluted weighted average shares outstanding are estimated to be in the range of 115.5 million to 117.5 million.

McKesson Financial Statement Overview

Summary

Strong and improving cash generation (TTM operating cash flow $7.5B; free cash flow $6.9B, ~94% of net income) and large-scale revenue growth support the score. The key offset is balance-sheet risk: persistent negative equity (TTM -$4.0B) and higher debt ($11.2B TTM) reduce financial flexibility despite steady (but thin) distributor margins.

Income Statement

74Positive

Balance Sheet

38Negative

Cash Flow

82Very Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue418.79B403.43B359.05B308.95B276.71B263.97B
Gross Profit15.37B14.55B12.48B12.20B11.87B12.65B
EBITDA7.55B7.18B5.25B4.67B5.49B2.87B
Net Income4.70B4.76B3.29B3.00B3.56B1.11B
Balance Sheet
Total Assets92.32B82.32B75.14B67.44B62.32B63.30B
Cash, Cash Equivalents and Short-Term Investments6.53B3.98B5.69B4.58B4.68B3.53B
Total Debt11.16B8.61B7.39B7.39B7.29B7.54B
Total Liabilities95.90B83.16B76.83B69.04B63.81B65.09B
Stockholders Equity-3.95B-2.17B-2.07B-1.97B-1.86B-2.27B
Cash Flow
Free Cash Flow6.91B5.41B5.23B3.63B4.60B3.90B
Operating Cash Flow7.50B6.16B6.08B4.31B5.16B4.43B
Investing Cash Flow-188.00M-3.43B-733.00M-1.07B-542.00M-89.00M
Financing Cash Flow-4.79B-4.63B-3.96B-3.34B-4.37B-6.32B

McKesson Technical Analysis

Technical Analysis SentimentPositive
Last Price1105.04

Price Trends

50DMA959.03Positive
100DMA902.73Positive
200DMA874.50Positive

Market Momentum

MACD39.25Negative
RSI75.24Negative
STOCH80.03Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MCK, the sentiment is Positive. The current price of 1105.04 is above the 20-day moving average (MA) of 1033.08, above the 50-day MA of 959.03, and above the 200-day MA of 874.50, indicating a bullish trend. The MACD of 39.25 indicates Negative momentum. The RSI at 75.24 is Negative, neither overbought nor oversold. The STOCH value of 80.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MCK.

McKesson Risk Analysis

McKesson disclosed 38 risk factors in its most recent earnings report. McKesson reported the most risks in the "Production" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Production - Risks related to the company’s ability to manufacture goods and services

Latest Risks Added

1 New Risk
1.Governance issues and regulations, including those related to social issues, climate change, and sustainability, and stakeholder response thereto may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.Q1, 2024

McKesson Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MCK against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GRDNGRDN74Outperform$3.13B41.8731.83%―4.85%83.17%
CAHCAH73Outperform$65.61B36.58-62.56%0.72%10.00%16.74%
PBHPBH68Neutral$2.28B14.658.19%―5.10%-19.73%
MCKMCK68Neutral$127.58B28.38-161.18%0.31%8.19%21.01%
HSICHSIC65Neutral$9.39B22.8813.13%―6.15%15.68%
CORCOR64Neutral$68.11B19.88115.76%0.69%5.00%124.34%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%MCKCORCAHHSICPBHGRDNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MCK and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MCKMcKesson Corporation1105.04255.9130.14%
CORCencora, Inc.356.94-0.97-0.27%
CAHCardinal Health283.8578.2738.07%
HSICHenry Schein84.9614.3620.34%
PBHPrestige Consumer Healthcare48.00-10.49-17.93%
GRDNGuardian Pharmacy Services, Inc. Class A49.4321.8879.42%

McKesson Corporate Events

Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A Transactions

McKesson, CD&R to Acquire Option Care Health

Positive
Oct 6, 2026

On October 6, 2026, Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health, the largest independent U.S. provider of home and alternate site infusion services, for $32.05 per share in a deal valuing the company at about $5.8 billi...

Business Operations and StrategyRegulatory Filings and Compliance

McKesson Reports Recent Cybersecurity Incident Under Regulation FD

Negative
Aug 28, 2026

McKesson Corporation reported that on August 25, 2026, it discovered a cybersecurity incident affecting its information systems, and an investigation into the breach remains in its early stages. As of the date of the filing, the company has not concl...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026